U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.
Shares of FedEx Corporation FDX fell sharply in pre-market trading after the company posted weaker-than-expected earnings for its second quarter and lowered its full-year revenue outlook.
FedEx reported quarterly earnings of $3.99 per share, falling short of the Street's estimate of $4.19. The company reported quarterly sales of $22.20 billion which missed analyst expectations of $22.39 billion, according to Benzinga Pro.
FedEx shares dipped 9.6% to $253.10 in pre-market trading.
Here are some big stocks recording losses in today’s pre-market trading session.
- argenx SE ARGX shares tumbled 30.4% to $314.86 in pre-market trading after the company disclosed topline results from the ADDRESS study evaluating efgartigimod subcutaneous in adults with pemphigus vulgaris and pemphigus foliaceus.
- bluebird bio, Inc. BLUE shares dipped 30.4% to $1.69 in pre-market trading. bluebird bio priced $125 million public offering of 83,333,333 common shares at $1.50 per share.
- Vast Renewables Limited VSTE dipped 20.9% to $9.48 in pre-market after dipping 14% on Tuesday.
- Jin Medical International Ltd. ZJYL shares fell 11.7% to $100.60 in pre-market trading after gaining around 12% on Tuesday. Last Thursday, before the market open, the company announced that it had signed a preliminary Memorandum of Understanding (MOU) with Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.
- Immunovant, Inc. IMVT shares fell 10.5% to $37.15 in pre-market trading.
- Steelcase Inc. SCS shares dipped 10.2% to $11.41 in pre-market trading. Steelcase posted upbeat earnings for its third quarter, while sales missed estimates. The company said it sees fourth-quarter adjusted earnings of 19 cents to 23 cents per share on revenue of $765 million to $790 million.
- Roivant Sciences Ltd. ROIV shares fell 7.4% to $10.00 in pre-market trading.
- Biohaven Ltd. BHVN shares declined 6.1% to $36.03 in pre-market trading.
Now Read This: Winnebago Gears Up For Q1 Print; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts
Don’t forget to check out our premarket coverage here
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.